| | |
CUSIP NO. N01045108 | | Page 6 of 7 Pages |
Statement on Schedule 13D
This Amendment No. 13 (“Amendment No. 13”) amends and supplements the statement on Schedule 13D initially filed on September 22, 2014, as amended by Amendment No. 1 on Schedule 13D filed on February 17, 2015, as amended by Amendment No. 2 on Schedule 13D filed on May 27, 2015, as amended by Amendment No. 3 on Schedule 13D filed on October 16, 2015, as amended by Amendment No. 4 on Schedule 13D filed on December 17, 2015, as amended by Amendment No. 5 on Schedule 13D filed on February 3, 2017, as amended by Amendment No. 6 on Schedule 13D filed on February 21, 2018, as amended by Amendment No. 7 on Schedule 13D filed on April 4, 2018, as amended by Amendment No. 8 on Schedule 13D filed on September 19, 2018, as amended by Amendment No. 9 on Schedule 13D filed on September 26, 2018, as amended by Amendment No. 10 on Schedule 13D filed on October 3, 2018, as amended by Amendment No. 11 on Schedule 13D filed on April 2, 2019, and as amended by Amendment No. 12 on Schedule 13D filed on April 5, 2019 (as so amended, the “Schedule 13D”) on behalf of SGR Sagittarius Holding AG (“SGR”), AGUTH Holding GmbH (“AGUTH”) and Dr. h.c. Klaus Tschira relating to the beneficial ownership of common shares, par value €0.01 per share (the “Common Shares”) of Affimed N.V. (formerly Affimed Therapeutics B.V.), a Dutch public company with limited liability (naamloze vennootschap) (the “Issuer”). Harald Tschira and Udo Tschira are the heirs to Dr. h.c. Klaus Tschira and are filing this Amendment No. 13 together with SGR and AGUTH (collectively, the “Reporting Persons”). Except as set forth below, this Amendment No. 13 does not supplement, restate or amend any of the other information disclosed in the Schedule 13D. Capitalized terms not defined in this Amendment No. 13 have the meanings ascribed to them in the Schedule 13D.
ITEM 5. | INTEREST IN SECURITIES OF THE ISSUER. |
Paragraphs (a), (b) and (c) of Item 5 of the Schedule 13D are hereby amended and restated in their entirety as follows:
(a,b) Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person. Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person. The percentage listed in Row 13 for each Reporting Person was calculated based upon 62,430,106 Common Shares outstanding as of March 15, 2019, as reported in the Issuer’s Annual Report on Form20-F filed with the Securities and Exchange Commission on March 27, 2019.
(c) No Reporting Person, other than SGR as set forth in the table below, effected any transaction in the Common Shares since April 5, 2019 (the date of filing of Amendment No. 12):
| | | | | | | | |
Date of Sale | | Shares Sold (#) | | | Avg. Sale Price per Share ($) | |
4/5/2019 | | | 437,000 | | | | 4.0251 | |
4/8/2019 | | | 214,159 | | | | 4.0578 | |
Each of the above listed transactions was conducted in the ordinary course of business on the open market for cash, and sale prices do not reflect brokerage commissions paid.